Abstract
Neuroplasticity may have a core role in the pathophysiology of major depressive disorder (MDD), a concept supported by experimental studies that found that excessive cortisol secretion and/or excessive production of inflammatory cytokines impairs neuronal plasticity and neurogenesis in the hippocampus. The objective of this study was to examine how changes in the glucocorticoid and inflammatory systems may affect hippocampal volumes in MDD. A multimodal approach with structural neuroimaging of hippocampus and amygdala, measurement of peripheral inflammatory proteins interleukin (IL)-6 and C-reactive protein (CRP), glucocorticoid receptor (GR) mRNA expression, and expression of glucocorticoid-inducible genes (glucocorticoid-inducible genes Leucin Zipper (GILZ) and glucocorticoid-inducible kinase-1 (SGK-1)) was used in 40 patients with MDD and 43 healthy controls (HC). Patients with MDD showed smaller hippocampal volumes and increased inflammatory proteins IL-6 and CRP compared with HC. Childhood maltreatment was associated with increased CRP. Patients with MDD, who had less expression of the glucocorticoid-inducible genes GILZ or SGK-1 had smaller hippocampal volumes. Regression analysis showed a strong positive effect of GILZ and SGK-1 mRNA expression, and further inverse effects of IL-6 concentration, on hippocampal volumes. These findings suggest that childhood maltreatment, peripheral inflammatory and glucocorticoid markers and hippocampal volume are interrelated factors in the pathophysiology of MDD. Glucocorticoid-inducible genes GILZ and SGK-1 might be promising candidate markers for hippocampal volume changes relevant for diseases like MDD. Further studies need to explore the possible clinical usefulness of such a blood biomarker, for example, for diagnosis or prediction of therapy response.
Highlights
Major depressive disorder (MDD) is a serious psychiatric disorder with a high relapse rate and lifetime prevalence of 15%.1 Despite the experimental findings involving neuroplasticity in the pathophysiology of MDD,[2] to date this work has not been translated into the clinical setting in terms of elucidating a causal role for stress and inflammatory cytokines in mediating hippocampal changes
A significant effect was detected for diagnostic group on C-reactive protein (CRP); with patients with MDD showing higher CRP levels compared with controls (Fchange 1⁄4 5.4, rsquare 1⁄4 0.063, df 1⁄4 1, 79, P 1⁄4 0.023)
The smaller hippocampal volumes in patients with MDD were mainly seen in those patients who had less expression of glucocorticoid-inducible genes Leucin Zipper (GILZ) mRNA, or serum and glucocorticoid-inducible kinase-1 (SGK-1) mRNA respectively, as a marker of reduced activation of the glucocorticoid system compared with those with higher GILZ mRNA expression
Summary
Major depressive disorder (MDD) is a serious psychiatric disorder with a high relapse rate and lifetime prevalence of 15%.1 Despite the experimental findings involving neuroplasticity in the pathophysiology of MDD,[2] to date this work has not been translated into the clinical setting in terms of elucidating a causal role for stress and inflammatory cytokines in mediating hippocampal changes. Despite the experimental findings involving neuroplasticity in the pathophysiology of MDD,[2] to date this work has not been translated into the clinical setting in terms of elucidating a causal role for stress and inflammatory cytokines in mediating hippocampal changes. It is well established that depressed patients hypersecrete cortisol,[3] have impaired glucocorticoid receptor (GR) functioning,[4] have increased circulating concentrations of inflammatory cytokines[5] and C-reactive protein (CRP)[6] and have reduced hippocampal volumes.[7] It has been shown that hippocampal volume reduction is associated with exposure to stress[7] and that it is influenced by genetic variation.[8].
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.